Your search matched 4 results
The U.S. | Blog
Democrats have revealed that the next major legislative package—colloquially known as the infrastructure package—will likely include provisions to lower prescription drug prices.
As you may have read, the Biden administration announced last week that it will support a proposal to temporarily waive certain intellectual property (IP) protections for COVID-19 vaccines and therapies.
Within a few days of the Aduhelm approval, the conversation quickly shifted from the first treatment for Alzheimer’s disease to the exorbitant cost ($56,000 annually) and whether the budgetary impact on society of the drug’s broad label is worth the therapeutic outcomes.
In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.